tbuckley/cabot-search huggingface dataset:
Bcl-2, Bax, Bak levels in colon crypts and colon cancer risk factors in the markers of Adenomatous Polyps II Case-Control Study
Authors: Veronika Fedirko, Carrie R. Daniel, Roberd M. Bostick
Journal: Cancer Research (2006)

691  The development of treatable biomarkers of risk for colon cancer is urgently needed. To address these needs, we investigated expression levels of major apoptosis control proteins (pro-survival: bcl-2; pro-apoptotic: bak and bax) in colorectal tissue obtained from participants in a community, colonoscopy-based, case-control study (n = 49 cases and 154 controls) of incident, sporadic colorectal adenoma in 30-74 year old adults. Diet was assessed using a modified version of the Willett Food Frequency Questionnaire; lifestyle and eating/cooking habits were assessed with a standardized health questionnaire. Levels of bcl-2, bak, and bax were detected and quantified in biopsies of normal-appearing rectal tissue from the first 20 cases and 20 controls by automated immunohistochemical methods and image analysis. Mean levels of overall expression in colon crypts as well as the ratio of expression in the upper 40% of the crypts to the lower 60% were calculated; from these values, additional analysis variables were calculated to reflect the sum of pro-apoptotic proteins (bak + bax) and the ratios of pro-apoptotic to pro-survival proteins (bax/bcl-2, bak/bcl-2, and [bak+bax]/bcl). Proportional differences in log-transformed mean values between cases and controls were compared by t-test. In addition, mean levels of overall expression were compared across categories of various risk factors for colorectal neoplasms. Proportional differences in crude means between cases and controls were: bcl-2, -0.1%, p = 0.76; bak, 0.6%, p = 0.88; bax, 15.4%, p = 0.57; bak+bax, 12.2%, p = 0.53; bax/bcl-2, 25.8%, p = 0.30; bak/bcl-2, -1.26%, p = 0.88; and (bak+bax)/bcl-2, 21.3%, p = 0.33. Proportional differences in the ratio of expression of bcl-2, bak, and bax in the upper 40% of the crypts to the lower 60% in cases vs. controls were 12.5% (p=0.67), 19.1% (p=0.97), and 17.6% (p=0.19), respectively. Risk factors most closely associated with bcl-2 were total carbohydrate intake (p=0.03), total fat intake (p=0.04), and family history of colon cancer (p=0.09); with bak were total fiber intake (p=0.02), total calcium intake (p=0.14), dieting (p=0.08), weight-loss in the past 3 months (p=0.03), smoking (p=0.09), and family history of colon cancer (p=0.01); and with bax were weight loss in the past 3 months (p=0.12), dieting (p=0.08), total fiber intake (p=0.10), habit of eating vegetables broiled (p=0.03), and family history of colon cancer (p=0.01). These preliminary analyses suggest that expression in normal-appearing colorectal mucosa of bax and bcl-2 alone and in ratio with one another may be valid, modifiable biomarkers of risk for colorectal neoplasms.
META-ANALYSIS OF DIRECT ORAL ANTICOAGULANT VERSUS VITAMIN K ANTAGONIST AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Hiroki Ueyama, Toshiki Kuno, Tomo Ando, Alexandros Briasoulis, John Fox, Kentaro Hayashida, Hisato Takagi
Journal: Journal of the American College of Cardiology (2020)
HALFWAY IS NO WAY: SUCCESSFUL DILATION OF A PREVIOUSLY UNDILATABLE, UNDEREXPANDED LAD STENT USING LASER ATHERECTOMY &amp; CUTTING BALLOON WITH COMPLETE RESOLUTION OF SEVERE ANGINA
Authors: Isaac Tea, Apurva Patel, Joe Aoun, Faheemullah Beg, Alpesh Shah
Journal: Journal of the American College of Cardiology (2020)
Conscientious vaccination exemptions in kindergarten to eighth-grade children across Texas schools from 2012 to 2018: A regression analysis
Authors: Maike Morrison, Lauren A. Castro, Lauren Ancel Meyers
Journal: PLoS Medicine (2020)

As conscientious vaccination exemption (CVE) percentages rise across the United States, so does the risk and occurrence of outbreaks of vaccine-preventable diseases such as measles. In the state of Texas, the median CVE percentage across school systems more than doubled between 2012 and 2018. During this period, the proportion of schools surpassing a CVE percentage of 3% rose from 2% to 6% for public schools, 20% to 26% for private schools, and 17% to 22% for charter schools. The aim of this study was to investigate this phenomenon at a fine scale.
Solitary Penile Metastasis of Prostate Cancer on 18F-Fluciclovine PET/CT Imaging in a Patient With PSA of 1 ng/mL
Authors: Ali Salavati, Allyssa N. Schik, Yasemin Koksel, Mehmet Gencturk, Jerry W. Froelich
Journal: Clinical Nuclear Medicine (2020)

An 85-year-old asymptomatic man with suspected biochemical recurrence of prostate cancer underwent an F-fluciclovine PET/CT scan, which revealed a solitary suspicious tracer uptake in the dorsal right corporal body of the proximal pendulous penis. The patient underwent ultrasound-guided fine-needle aspiration of the penile lesion, which revealed metastatic prostate cancer. The patient had definitive external beam radiation therapy 3 years before the examination. At the time of scan, the prostatic-specific antigen (PSA) was only 1.0 ng/mL, although the PSA doubling time was 2.6 months. It is unusual to detect a solitary penile metastasis in a patient with a low level of PSA.
BASELINE AND CHANGES IN GUIDELINE DIRECTED MEDICAL THERAPY IN HFPEF AND HFREF: THE COAPT TRIAL
Authors: JoAnn Lindenfeld, Saibal Kar, None Kar, Scott Lim, Paul A. Grayburn, Aaron Crowley, Michael Mack, Gregg W. Stone, William Abraham
Journal: Journal of the American College of Cardiology (2020)
Allogeneic hematopoietic stem cell transplantation for cutaneous T-cell lymphoma (CTCL)
Authors: C. Hosing, M. Donato, I. F. Khouri, D. T. Chu, D. L. Bethancourt, S. Acholonu, S. Giralt, M. Duvic, R. E. Champlin
Journal: Journal of Clinical Oncology (2006)

7540 Background: Patients (pts.) with advanced CTCL have a poor prognosis. There has been limited experience with the use of allogeneic hematopoietic stem cell transplantation (HSCT) in these pts. We report the results of 11 pts. with advanced CTCL/Sezary syndrome who underwent allogeneic HSCT at our institution. Patients and Methods: All pts. signed informed consent. Median age at the time of HSCT was 50.5 years (range, 22–63). There were 8 F/3M. All were diagnosed with stage IV disease. The median number of prior treatment regimens was 5.5 (range, 3–11). Treatment regimens included PUVA, TSEB, ECP, topical therapy, retinoids, bexarotene, denileukin diftitox, and multiagent chemotherapy. Seven pts. had a PR to treatment administered prior to transplantation, 2 pts. were in CRu and 2 pts. had SD. The conditioning regimen was fludarabine (125 mg/m 2 ), melphalan 140 mg/m 2 in 8 pts., fludarabine (125 mg/m 2 ), cyclophosphamide (3 g/m 2 ) ± rituximab in 2 pts., and fludarabine (120 mg/m 2 ), busulfan (11.2 mg/m 2 ) in 1 pt. Patients who received unrelated or mismatched related stem cells also received ATG. GVHD prophylaxis was with tacrolimus/methotrexate in all patients. Results: Ten of 11 pts. engrafted with a median time to ANC &gt;500 mm 3 of 12 days (range, 8–14). One pt. died at 17 days post transplant without engraftment due to sepsis. One pt. developed autologous reconstitution and underwent a 2nd allogeneic HSCT procedure and remains in CR at 3 years post transplant. Of the remaining 9 pts., 7 achieved full donor chimerism and 2 pts. were mixed chimera. At the time of this report 4 of 11 pts. have died. Cause of death was sepsis in 2, fungal pneumonia in 1, and PD in 1 pt. Three pts. relapsed post transplant, all 3 were induced back in to a CR by tapering of immunosuppression (2) or DLI (1). Overall 7 pts. continue to be alive and remission with a median follow up of 2.9 years (range, 3 months to 4.4 years). Four of 7 pts. have cGVHD requiring treatment (Table). Conclusions: Allogeneic HSCT is an effective therapy for refractory CTCL/SS and merits further evaluation. [Table: see text] No significant financial relationships to disclose.
CLO20-061: A Meta-Analysis on the Safety of Panobinostat Compared to Eltozumab and Ixazomib for the Treatment of Multiple Myeloma
Authors: Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Mishal Shaukat, Qian Zhang
Journal: Journal of the National Comprehensive Cancer Network (2020)
IMPACT OF TRANSCATHETER PULMONARY ARTERY INTERVENTION FOLLOWING SUPERIOR CAVOPULMONARY CONNECTION ON DOWNSTREAM PULMONARY ARTERY GROWTH
Authors: Kasey Chaszczewski, Jing Huang, Stephanie Fuller, Christopher Smith, Yoav Dori, Andrew C. Glatz, Matthew J. Gillespie, Jonathan J. Rome, Michael L. O'Byrne
Journal: Journal of the American College of Cardiology (2020)
NO FLOW IN THE DISTAL CORONARY SEGMENT AND REVERSED FLOW AT THE PROXIMAL SEGMENT ARE THE MECHANISMS OF CHEST PAIN IN PATIENTS WITH AORTIC STENOSIS AND PATENT CORONARY ARTERIES
Authors: Duy Chung, Luan Ngo, Loc Tri Vu, Thach N. Nguyen, Gianluca Rigatelli
Journal: Journal of the American College of Cardiology (2020)
Other and other waters in the river: Autism and the futility of prediction
Authors: Matthew K. Belmonte
Journal: Behavioral and Brain Sciences (2020)

Abstract Autism has been described as a neural deficit in prediction, people with autism manifest low perceptual construal and are impaired at traversing psychological distances, and Gilead et al.'s hierarchy from iconic to multimodal to fully abstract, socially communicated representations is exactly the hierarchy of representational impairment in autism, making autism a natural behavioural and neurophysiological test case for the prediction–abstraction relationship.
Sentinel lymph node biopsy for clinically N0 oral squamous cell carcinoma.
Authors: Hiroyuki Goda, Koh-ichi Nakashiro, Ryota Oka, Satoru Shintani, Hiroyuki Hamakawa
Journal: Journal of Clinical Oncology (2012)

5584 Background: Regionallymph node metastasis is an important prognostic factor in oral squamous cell carcinoma (OSCC). Sentinel lymph node biopsy (SLNB) is a widely accepted procedure in various human malignancies. In clinically N0 (cN0) OSCC cases, SLNB has received considerable attention for its role in deciding whether to perform neck dissection. In this study, we assessed the efficiency of SLNB for cN0 OSCC case in a single-institution experience. Methods: 100 patients with cN0 OSCC underwent SLNB between 2001 and 2011, of which 95 were clinically T1 and T2. The primary site was tongue, gingiva, oral floor, buccal mucosa, and lip in 50%, 36%, 8%, 5%, and 1%, respectively. The location of sentinel lymph node (SLN) was determined by radioisotope (RI) method with preoperative lymphoscintigraphy and intraoperative use of a handheld gamma probe and/or dye method, and evaluated by histopathological examination and genetic analysis. Results: SLNB was performed with RI and dye method (79%), only dye method (14%), or only RI method (7%). SLN was successfully identified with RI method (100%) and dye method (71%). The average number of SLN was 2.5 with dye method and 1.9 with RI method. The rate of SLN identified side was 84% in ipsilateral, 10% in bilateral, and 6% in contralateral. Fifteen of 100 patients (15%) had metastasis-positive SLN, and 3 patients was up-grade to stage III and others to stage IVA. Eight patients with negative SLN developed latent neck lymph node metastasis. The sensitivity, specificity, accuracy, and negative predictive value was 65% (15/23), 100% (77/77), 92% (92/100) and 91% (77/85). Disease specific survival rate for SLNB-negative patients were 98% (79/81), and for SLNB-positive patients were 73% (11/15), respectively. Conclusions: SLNB is a minimally invasive and highly reliable means of staging the cN0 neck for patients with OSCC. Patients with negative SLNB showed more excellent neck control rate and SLNB provides more accurate staging than elective neck dissection or wait and see.
Abstract 15591: Lowering of Lipoprotein (a) Particle Number by Lipid Apheresis
Authors: Amanjot S Lehil, Patrick M Moriarty
Journal: Circulation (2013)

BACKGROUND: Lipid apheresis is an established therapy for lowering of LDL-C, LDL-P and other lipoproteins, but there is lack of data on reduction in Lp(a)-P with lipid apheresis. Lp(a) is a recogni...
QUANTITATIVE FLOW RATIO ACCORDING TO THREE-DIMENSIONAL QUANTITATIVE CORONARY ANGIOGRAPHY DEFINED SEVERITY OF STENOSIS IN A COHORT OF WOMEN WITH STABLE CORONARY ARTERY DISEASE
Authors: Mauro Gitto, Yuichi Saito, Marabel Schneider, Nikolaos Papoutsidakis, Scott Ardito, Marianne McCarthy, Ecaterina Cristea, Alexandra Lansky, S. Elissa Altin
Journal: Journal of the American College of Cardiology (2020)
Circulating tumor cells and T790M in metastatic non-small cell lung cancer patients with <i>EGFR</i> mutations and acquired resistance to TKI.
Authors: Kazutoshi Isobe, Yoshinobu Hata, Keita Sato, Keishi Sugino, Go Sano, Susumu Sakamoto, Yujiro Takai, Kazutoshi Shibuya, Keigo Takagi, Sakae Homma
Journal: Journal of Clinical Oncology (2012)

e18127 Background: This study assessed correlations between the presence of circulating tumor cells (CTCs), detection of T790M in organs with metastases or circulating-free DNA (cfDNA), and prognosis in metastatic NSCLC patients with acquired resistance to EGFR-TKI. Methods: Metastatic NSCLC patients with activating EGFR mutations, who initially responded but subsequently experienced disease progression while on EGFR-TKI treatment, were defined as having ‘acquired resistance’. Blood samples were collected after development of such acquired resistance and CTCs were counted using the CellSearch system (Veridex). At the same time, T790M in affected organs or cfDNA was analyzed with cycleave real-time PCR assay and fragment analysis. Results: : Six men and 14 women with a mean age of 63.5 yrs (22-84) were enrolled. Histological subtypes were adenocarcinoma in 19 and squamous cell carcinoma in the remaining one. Clinical stages were stage IV in 14 and recurrence with distant metastases after surgical resection in 6. EGFR mutations in tumors at the primary site were G719C in 1, exon 19 deletion in 7, L858R in 10, and G791C + L858R in 2. CTCs were detected in 8 (40%). Numbers of CTCs (per 7.5 ml blood) were 1 in 4 cases, and 3, 4, 8, and 24 in 1 case each. Patients without CTCs survived significantly longer than those with CTCs (≥1 per 7.5 ml). Mean survival time from first detection of CTCs was 3.0 months in patients with CTCs and not reached in patients without CTCs (p &lt; 0.001). T790M was detected in 6 cases (30%). T790M was found in 75% (n = 6/8) of patients without CTCs but in 0% (n = 0/12) of those with CTCs (p &lt; 0.05). Conclusions: The presence of CTCs was correlated with poorly prognosis and lack of T790M in affected organs or cfDNA. The presence of CTCs was informative for distinguishing patients with or without T790M.
Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib
Authors: Kevin L Winthrop, Ann Wouters, Ernest H Choy, Connie Chen, Pinaki Biswas, Lisy Wang, Koshika Soma, Elie Needle, Hernan Valdez, William FC Rigby
Journal: Annals of the Rheumatic Diseases (2020)

Herpes zoster (HZ) incidence is higher in patients with rheumatoid arthritis (RA) compared with the general population,1 and it may be further increased with disease-modifying antirheumatic drugs (DMARDs).2 Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Real-world data indicate that HZ incidence is approximately twofold higher with tofacitinib versus biologic DMARDs (bDMARDs).3 

Current American College of Rheumatology guidelines conditionally recommend that patients with RA aged ≥50 years receive HZ vaccine prior to tofacitinib or bDMARDs.4 We previously evaluated the immunogenicity of a live attenuated zoster vaccine (LZV), administered 2–3 weeks prior to tofacitinib or placebo with background conventional synthetic DMARDs. Both groups had similar varicella zoster virus (VZV)-specific immune responses, and overall immune responses were comparable with those of healthy volunteers in previous studies.5 We have now followed this patient cohort in an open-label, long-term extension (LTE) study of tofacitinib.

Patients enrolled in the index study (A3921237; NCT02147587)5 could join ORAL Sequel (LTE study; A3921024; NCT00413699) 14 weeks post-vaccination, where they received open-label tofacitinib 5 or 10 mg two times per day (online supplementary figure S1); background RA therapy was also allowed. Patients were followed for 27 months. Post-vaccination, adverse events (AEs), including discontinuations due to AEs, were recorded during the study within 28 days of …
PROGNOSTIC IMPACT OF LEFT VENTRICULAR EJECTION FRACTION AFTER UNPROTECTED LEFT MAIN CORONARY ARTERY STENTING USING SECOND GENERATION DRUG ELUTING STENT
Authors: Kohei Osakada, Masanobu Ohya, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Kazushige Kadota
Journal: Journal of the American College of Cardiology (2020)
Staging of small cell lung cancer (SCLC): Comparison of two criteria by survival analysis
Authors: R. Williams, N. Eskandari, A. Kendall
Journal: Journal of Clinical Oncology (2006)

17030 Background: Consistent staging of SCLC is pertinent to the selection and evaluation of treatment regimens. The Veterans Administration Lung Study Group (VALG) defines patients with limited disease (LD) as those with tumor limited to one hemithorax. In contrast, the International Association for the Study of Lung Cancer (IASLC), basically a TNM method, defines limited disease as those with no distant metastases. We assessed the survival of intermediate patients (ID), defined as those who qualified as LD by the IASLC but not the VALG criteria. Methods: A retrospective chart review was done on 252 patients consecutively diagnosed with SCLC between 1990 and 2004 at a Northern California hospital. Kaplan Meier analysis and log-rank tests were used to compare the survival of ID and LD patients. We also compared survival of both ID and LD to patients with extensive disease (ED). Multivariate Cox regression analysis was used to incorporate clinically relevant data. Bonferroni adjustment was made for multiple comparisons. Results: We defined 93 patients as LD, 32 as ID and 127 as ED. Median survival of patients with ID was 12 months (95% CI 9–16 months) and for LD 11 months (95% CI 9–13 months). Median survival for patients with ED was 6 months (95% CI 4–7 months) and significantly shorter (P &lt; .0001) than either ID or LD. Conclusions: The present study questions the inclusiveness of the VALG definition of LD concurs with prior findings from Germany (Lung Cancer 37:271, 2002). SCLC patients should be staged by the IASLC criteria when being evaluated for treatment regimens. No significant financial relationships to disclose.
Melatonin inhibits cytosolic mitochondrial DNA–induced neuroinflammatory signaling in accelerated aging and neurodegeneration
Authors: Abhishek Jauhari, Sergei V. Baranov, Yalikun Suofu, Jinho Kim, Tanisha Singh, Svitlana Yablonska, Fang Li, Xiaomin Wang, Patrick Oberly, M. Beth Minnigh, Samuel M. Poloyac, Diane L. Carlisle, Robert M. Friedlander
Journal: Journal of Clinical Investigation (2020)

Chronic inflammation is a pathologic feature of neurodegeneration and aging; however, the mechanism regulating this process is not understood. Melatonin, an endogenous free radical scavenger synthesized by neuronal mitochondria, decreases with aging and neurodegeneration. We proposed that insufficient melatonin levels impair mitochondrial homeostasis, resulting in mitochondrial DNA (mtDNA) release and activation of cytosolic DNA-mediated inflammatory response in neurons. We found increased mitochondrial oxidative stress and decreased mitochondrial membrane potential, with higher mtDNA release in brain and primary cerebro-cortical neurons of melatonin-deficient aralkylamine N-acetyltransferase (AANAT) knockout mice. Cytosolic mtDNA activated the cGAS/STING/IRF3 pathway, stimulating inflammatory cytokine generation. We found that Huntington's disease mice had increased mtDNA release, cGAS activation, and inflammation, all inhibited by exogenous melatonin. Thus, we demonstrated that cytosolic mtDNA activated the inflammatory response in aging and neurodegeneration, a process modulated by melatonin. Furthermore, our data suggest that AANAT knockout mice are a model of accelerated aging.
EFFECT OF HIGH PLATELET REACTIVITY ON ADVERSE EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTION FOR LEFT MAIN CORONARY ARTERY DISEASE: THE ADAPT-DES STUDY
Authors: Danial Saleem, Mahesh Madhavan, Bjorn Redfors, Thomas Stuckey, Bernhard Witzenbichler, Giora Weisz, Michael Rinaldi, Mengdan Liu, Dimitrios Karmpaliotis, Ajay Kirtane, Gregg Stone
Journal: Journal of the American College of Cardiology (2020)
PHYSICAL FRAILTY AND FIVE-YEAR OUTCOMES AMONG OLDER ADULTS IN THE NATIONAL HEALTH AND AGING TRENDS STUDY (NHATS)
Authors: Abdulla Damluji, Shang-En Chung, Rani K. Hasan, Jon Resar, Wayne B. Batchelor, Mauro Moscucci, Christopher O'Connor, Jeremy Walston, Qian-Li Xue
Journal: Journal of the American College of Cardiology (2020)
ACUTE RECOIL AND LATE RECOIL AFTER ORSIRO CORONARY DRUG-ELUTING STENT IMPLANTATION
Authors: Takao Sato, Yoshifusa Aizawa, Yuji Taya, Yusuke Ohta, Sho Yuasa, Minoru Takahashi, Masaaki Okabe
Journal: Journal of the American College of Cardiology (2020)
Hypertension and cardiotoxicity in metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU).
Authors: Veronica Prati, Cinzia Ortega, Valentina Ballatore, Danilo Galizia, Fiorella Ruatta, Alessandro Bonzano, Sandra Aliberti, Giovanni Grignani, Massimo Aglietta
Journal: Journal of Clinical Oncology (2012)

e15073 Background: Recent data have shown that cardiotoxicity (CHFcongestive heart failure, CADcoronary artery disease)could be an important side-effect in patients (pts) with RCC treated with tyrosine kinase inhibitors (TKIs). LVEF(Left ventricular ejection fraction)reduction may occur in up to 10% of pts treated with SU and uncontrolled hypertension could worse this side-effect. This complication is reversible with TKI interruption and appropriate antihypertensive therapy. Methods: We have prospectively analyzed patients receiving SU as a first-line treatment for mRCC. Between April 2007 and December 2011,31 consecutive pts, median age 67 yrs (41-80) were treated with SU at the standard dose of 50 mg/day,4 weeks on and 2 weeks off. We recorded for all pts CAD risk factors, preexisting hypertension,rhythm disturbances and heart failure. ECG, echocardiography and cardiology consultation were performed at baseline, and every three months until progression or permanent SU discontinuation. We searched correlations between cardiotoxicity onset and hypertension. Results were assessed with paired Student’s t-test and Chi-square test. Results: At baseline,we found 22 pts (71%) with hypertensive disease (HD). The median duration treatment was 8,3 months(22-0,4).On TKI therapy 6/22 pts (27.2%) worsened the preexisting HD, which was controlled with adequate treatment according to American Heart Association guidelines, without determining treatment discontinuation. Furthermore 6/31 pts (19%) developed this adverse event. In 14/31 pts (45%) we showed a median ≥ 10% LVEF reduction compared to baseline value (p=.001); 13/31 pts were asymptomatic and only one presented symptoms of CHF and discontinued the treatment. In this study, history of HD,worsening of preexisting HD or development of HD are not predictive for &gt;10% LVEF reduction (p=ns). Conclusions: In pts with mRCC receiving SU as a first-line treatment, HD is not predictive for LVEF reduction. Moreover on TKI therapy there is a statistically significant LVEF reduction, but this adverse event does not determine a treatment discontinuation. A cardiovascular monitoring during SU treatment may reduce this event in order to allow an adequate treatment.
CCL2 mitigates cyclic AMP‐suppressed Th2 immune response in human dendritic cells
Authors: Byoungjae Kim, Ji Woo Yeon, Ji Hyung Lee, Hyun‐Ji Lee, Junhyoung Byun, Kijeong Lee, Eyal Raz, Sang Hag Lee, Seung‐Kuk Baek, Tae Hoon Kim
Journal: Allergy (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.